Literature DB >> 7904601

Expression of multiple somatostatin receptor genes in AtT-20 cells. Evidence for a novel somatostatin-28 selective receptor subtype.

Y C Patel1, R Panetta, E Escher, M Greenwood, C B Srikant.   

Abstract

The pattern of expression of somatostatin receptor (SSTR) genes and gene products in AtT-20 cells was characterized in an attempt to explain the SST-28 binding selectivity that typifies these cells. AtT-20 cells expressed multiple SSTR mRNAs. Paradoxically, this included mRNA for three of the four SST-14 selective receptors: SSTR2 ( +), SSTR1 (+), SSTR4 (+). The SST-28 selective SSTR5 was expressed as a 3.8-kilobase (kb) transcript of relatively low abundance (+) in contrast to normal mouse pituitary which displayed high levels ( ) of a 2.4-kb SSTR5 mRNA. Immunoblot analysis of solubilized membranes with an antipeptide SSTR2 antibody revealed a single SSTR2 protein of 72 +/- 2 kDa. Preincubation of AtT-20 cell membranes with SSTR2 antibody reduced 125I-[Leu8,D-Trp22,Tyr25]SST-28 binding sites by 38%. Residual binding sites exhibited a 4.9-fold increase in affinity for SST-28, a 2.6-fold decrease in affinity for SST-14, and an SST-28:SST-14 potency ratio of 40:1 compared with a potency ratio of 3.5:1 in control membranes. These results demonstrate the expression of four SSTR genes in AtT-20 cells of which SSTR2 predominates. Blockade of SSTR2 with antibody exposes high affinity SST-28 selective sites with comparable binding characteristics to those reported for cloned SSTR5. These SST-28 binding sites may arise from a SSTR5 variant encoded by a high molecular weight 3.8-kb transcript or more likely from another as yet undiscovered member of the SST-28 selective SSTR subfamily.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7904601

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Activation of human D3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells.

Authors:  E V Kuzhikandathil; G S Oxford
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

2.  Genes expressed in the mouse pituitary corticotrope AtT-20/D-16v tumor cell line.

Authors:  M R Schiller
Journal:  Pituitary       Date:  2000-11       Impact factor: 4.107

3.  Different G proteins mediate somatostatin-induced inward rectifier K+ currents in murine brain and endocrine cells.

Authors:  K Takano; J Yasufuku-Takano; T Kozasa; S Nakajima; Y Nakajima
Journal:  J Physiol       Date:  1997-08-01       Impact factor: 5.182

4.  Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Dominique Fehlmann; Daniel Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-15       Impact factor: 3.000

5.  Localization of the somatostatin receptor SST2A in rat brain using a specific anti-peptide antibody.

Authors:  P Dournaud; Y Z Gu; A Schonbrunn; J Mazella; G S Tannenbaum; A Beaudet
Journal:  J Neurosci       Date:  1996-07-15       Impact factor: 6.167

Review 6.  Somatostatin.

Authors:  T Reisine
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

Review 7.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 8.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

9.  Tyrosine phosphorylation of Kir3 following kappa-opioid receptor activation of p38 MAPK causes heterologous desensitization.

Authors:  Cecilea C Clayton; Mei Xu; Charles Chavkin
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

10.  Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Caroline Nunn; Dominique Fehlmann; Daniel Langenegger; Edi Schuepbach; Daniel Hoyer
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.